Home/Merck & Co. Inc./Q3-2025
◆ MIXED○ HYPE2025-10-30

Merck & Co. Inc. Q3-2025

Health Care · Pharmaceuticals

Revenue
$17.3B
YoY Growth
4.0%
EPS
$2.58
Gross Margin
81.9%
Revenue by Segment
Pharmaceutical
+4%$15.6B
Animal Health
+9%$1.6B
KEYTRUDA
+10%$8.1B
GARDASIL/GARDASIL 9
-24%$1.7B
WINREVAIR
+141%$360M
CAPVAXIVE
$244M
JANUVIA/JANUMET
+29%$624M
LAGEVRIO
-64%$138M
WELIREG
+42%$196M
Livestock
+16%$1.0B
Companion Animal
-2%$592M

Operator Signal: MIXED

KEYTRUDA franchise keeps powering ahead at 10% growth, and WINREVAIR's 141% ramp is validating the cardiovascular expansion thesis. But GARDASIL's 24% decline in China is a structural headwind, not a blip. The $70B+ domestic manufacturing commitment signals long-term confidence but compresses near-term margins.

Founder Implication

If you're selling into pharma or hospital systems, KEYTRUDA subcutaneous approval (one-minute administration) is about to reshape infusion center economics — watch for procurement cycle changes in oncology clinics.

AI Intelligence

○ HYPE

No AI-specific mentions in the earnings release. Merck's focus remains on traditional drug development, clinical trials, and manufacturing rather than AI integration or deployment.

Mentions: 0

Competitor Intelligence

Johnson & Johnson1x mentioned
NEUTRAL
“Marketing rights in former territories of the Company reverted to Johnson & Johnson on Oct. 1, 2024.”
AstraZeneca3x mentioned
NEUTRAL
“Amendment to the collaboration agreement with AstraZeneca, which discontinued the provisions whereby the Company shared revenue and costs”
Daiichi Sankyo3x mentioned
BULLISH
“$170 million of income recognized in 2024 related to a payment received from Daiichi Sankyo associated with the expansion of an existing agreement”
Bayer1x mentioned
NEUTRAL
“Alliance Revenue represents the Company's share of profits from sales in Bayer's marketing territories”
Verona Pharma3x mentioned
BULLISH
“Completed Acquisition of Verona Pharma and Its First-In-Class COPD Maintenance Treatment for Adults, OHTUVAYRE, in October”
LaNova Medicines4x mentioned
NEUTRAL
“Charge of $0.10 per share for milestone payment to LaNova for Technology Transfer for MK-2010”
Hengrui Pharma2x mentioned
NEUTRAL
“$200 million for an upfront payment for a license agreement with Jiangsu Hengrui Pharmaceuticals Co., Ltd.”

What They Actually Said

“In the third quarter, we continued to execute on our strategy with important pipeline advancements, significant approvals and successful new product launches.”

— Robert M. Davis, CEO
growth-signalproduct-launch

“We're securing our future by making important investments in our pipeline including through compelling, strategic business development like our completed acquisition of Verona Pharma and expanded U.S. manufacturing and R&D spending.”

— Robert M. Davis, CEO
m-and-agrowth-signal

“With each milestone we achieve, my conviction that we're well-positioned to drive the next chapter of success for our Company increases.”

— Robert M. Davis, CEO
guidancegrowth-signal

Forward Guidance

RAISED
Now Expects Worldwide Sales To Be Between $64.5 Billion and $65.0 Billion(full year)
RAISED
Raises and Narrows Expected Non-GAAP EPS Range To Be Between $8.93 and $8.98(full year)
MAINTAINED
Non-GAAP Gross margin Approximately 82%(full year)
MAINTAINED
Non-GAAP Operating expenses $25.9 billion to $26.4 billion(full year)
LOWERED
Non-GAAP Effective tax rate 14.0% to 15.0%, lowered from 15.0% to 16.0%(full year)

Who Ran This Call

DynamicCEO-Led Call
CEO Share100%
Robert M. DavisCEO
CONFIDENT120 words
Robert M. Davis: “my conviction that we're well-positioned to drive the next chapter of success increases”
Themes
m-and-apricing-powerguidance-raisedproduct-launchchina-exposurefx-headwindscapital-returnsregulatory-risktariffs